PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.

@article{Hoeller2011PCM1JAK2fusionAP,
  title={PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.},
  author={Sylvia Hoeller and Christoph Walz and Andreas Reiter and Stephan R Dirnhofer and Alexandar Tzankov},
  journal={Expert opinion on therapeutic targets},
  year={2011},
  volume={15 1},
  pages={53-62}
}
IMPORTANCE OF THE FIELD Activating mutations of the JAK2 gene are of tumorigenic significance in myeloproliferative neoplasms. Translocations involving the JAK2 locus are of oncogenic importance in acute leukemias, myelodysplastic/myeloproliferative diseases and T-cell lymphomas. JAK2 locus gains, which are recurrent in Hodgkin's- and primary mediastinal B-cell lymphoma, are also efficient mechanisms of JAK2 activation. Recently, specific drugs blocking JAK2 have been developed and are… CONTINUE READING